Redeye strengthens its positive view of CombinedX and raises its Base Case and forecasts following a solid Q4 report. Partly thanks to reduced employee churn, organic growth increased to 16.5% and the adjusted EBIT margin to 11.2%, beating our forecasts. Despite the surge in the share price following the Q4, CombinedX is still trading at low multiples.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

CombinedX - Solid Rebound

© Modular Finance, source Nordic Press Releases